6-(5-Bromo-pyridin-3-yl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid amide (100 mg, 0.30 mmol, which is prepared according to the procedure for Step 1 to Step 4 of Example 15) is dissolved into 2 mL of dioxane/water (9:1). 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyran (94.6 mg, 0.45 mmol), K3PO4 (318 mg, 1.50 mmol) and PdCl2(DPPF)CH2Cl2 (24.5 mg, 0.03 mmol) are added. The mixture is heated at 100° C. for 48 hrs. The mixture is diluted with 100 mL EtOAc and quenched with 100 mL of saturated aqueous NH4Cl. The organic phase is washed with 2×20 mL of H2O and 1×20 mL of brine. The organic phase is dried with MgSO4, filtered and concentrated. The crude material is applied to a silica preparative TLC plate and purified twice to give 52.1 mg of the titled product.
